Discounted Cash Flow (DCF) Analysis Levered
Titan Pharmaceuticals, Inc. (TTNP)
$0.764
-0.01 (-0.65%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 5.91 | 3.61 | 4.84 | 1.53 | 0.56 | 0.37 | 0.24 | 0.16 | 0.10 | 0.07 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | -8.43 | -15.44 | -17.20 | -7.90 | -8.18 | -2.13 | -1.40 | -0.92 | -0.61 | -0.40 |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | -0.42 | -0.26 | -0.54 | -0.02 | -0.04 | -0.02 | -0.02 | -0.01 | -0.01 | -0 |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | -8.85 | -15.70 | -17.74 | -7.92 | -8.22 | -2.16 | -1.42 | -0.93 | -0.61 | -0.40 |
Weighted Average Cost Of Capital
| Share price | $ 0.764 |
|---|---|
| Beta | 1.102 |
| Diluted Shares Outstanding | 13.43 |
| Cost of Debt | |
| Tax Rate | 0.00 |
| After-tax Cost of Debt | 5.00% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 8.840 |
| Total Debt | 0.19 |
| Total Equity | 10.26 |
| Total Capital | 10.45 |
| Debt Weighting | 1.79 |
| Equity Weighting | 98.21 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 5.91 | 3.61 | 4.84 | 1.53 | 0.56 | 0.37 | 0.24 | 0.16 | 0.10 | 0.07 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -8.43 | -15.44 | -17.20 | -7.90 | -8.18 | -2.13 | -1.40 | -0.92 | -0.61 | -0.40 |
| Capital Expenditure | -0.42 | -0.26 | -0.54 | -0.02 | -0.04 | -0.02 | -0.02 | -0.01 | -0.01 | -0 |
| Free Cash Flow | -8.85 | -15.70 | -17.74 | -7.92 | -8.22 | -2.16 | -1.42 | -0.93 | -0.61 | -0.40 |
| WACC | ||||||||||
| PV LFCF | -1.98 | -1.20 | -0.73 | -0.44 | -0.27 | |||||
| SUM PV LFCF | -4.62 |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 8.77 |
| Free cash flow (t + 1) | -0.41 |
| Terminal Value | -6.09 |
| Present Value of Terminal Value | -4 |
Intrinsic Value
| Enterprise Value | -8.61 |
|---|---|
| Net Debt | -2.75 |
| Equity Value | -5.86 |
| Shares Outstanding | 13.43 |
| Equity Value Per Share | -0.44 |